EP0666761A4 - STIMULATION OF AN ANTI-TUMOR RESPONSE OF T-LYMPHOCYTES USING ANTI-IDIOTYPIC ANTIBODIES. - Google Patents

STIMULATION OF AN ANTI-TUMOR RESPONSE OF T-LYMPHOCYTES USING ANTI-IDIOTYPIC ANTIBODIES.

Info

Publication number
EP0666761A4
EP0666761A4 EP93920425A EP93920425A EP0666761A4 EP 0666761 A4 EP0666761 A4 EP 0666761A4 EP 93920425 A EP93920425 A EP 93920425A EP 93920425 A EP93920425 A EP 93920425A EP 0666761 A4 EP0666761 A4 EP 0666761A4
Authority
EP
European Patent Office
Prior art keywords
antitumor
stimulation
cell response
idiotypic antibodies
idiotypic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93920425A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0666761A1 (en
Inventor
Lynn E Spitler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenner Technologies
Original Assignee
Jenner Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenner Technologies filed Critical Jenner Technologies
Publication of EP0666761A1 publication Critical patent/EP0666761A1/en
Publication of EP0666761A4 publication Critical patent/EP0666761A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP93920425A 1992-08-31 1993-08-31 STIMULATION OF AN ANTI-TUMOR RESPONSE OF T-LYMPHOCYTES USING ANTI-IDIOTYPIC ANTIBODIES. Withdrawn EP0666761A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US938079 1978-08-30
US93807992A 1992-08-31 1992-08-31
PCT/US1993/008163 WO1994005329A1 (en) 1992-08-31 1993-08-31 Stimulation of an antitumor t-cell response using anti-idiotypic antibodies

Publications (2)

Publication Number Publication Date
EP0666761A1 EP0666761A1 (en) 1995-08-16
EP0666761A4 true EP0666761A4 (en) 1996-07-17

Family

ID=25470841

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93920425A Withdrawn EP0666761A4 (en) 1992-08-31 1993-08-31 STIMULATION OF AN ANTI-TUMOR RESPONSE OF T-LYMPHOCYTES USING ANTI-IDIOTYPIC ANTIBODIES.

Country Status (5)

Country Link
EP (1) EP0666761A4 (ja)
JP (1) JPH08502954A (ja)
AU (1) AU5097393A (ja)
CA (1) CA2139743A1 (ja)
WO (1) WO1994005329A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US7354587B1 (en) 1994-07-06 2008-04-08 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
JPH10511846A (ja) 1994-12-28 1998-11-17 ユニバーシティ オブ ケンタッキー ヒトガン胎児性抗原に関連する組換えモノクローナル抗イディオタイプ抗体３ｈ１配列
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
AU2994599A (en) * 1998-03-06 1999-09-20 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
US6376654B1 (en) 1999-08-13 2002-04-23 Molecular Discoveries, Llc Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
US7226750B1 (en) 2000-08-08 2007-06-05 Molecular Discoveries, Inc. Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8562988B2 (en) 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US8435539B2 (en) 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
EP2326346A4 (en) 2008-08-20 2012-06-13 Ibc Pharmaceuticals Inc DOCK-AND-LOCK (DNL) ACCOSTAGE AND LOCK VACCINES FOR CANCER THERAPY

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BHATTACHARYA-CHATTERJEE M. ET AL., INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 7, no. 4, 1991, pages 289 - 302, XP000570399 *
HERLYN D.ET AL., INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 7, no. 4, 1991, pages 245 - 257, XP000569562 *
RAYCHAUDHURI S. ET AL., CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 9, no. 2, 1989, pages 109 - 124, XP000569759 *
RAYCHAUDHURI S. ET AL., JOURNAL OF IMMUNOLOGY, vol. 139, no. 6, 15 September 1987 (1987-09-15), BALTIMORE US, pages 2096 - 2102, XP002003096 *
See also references of WO9405329A1 *

Also Published As

Publication number Publication date
WO1994005329A1 (en) 1994-03-17
CA2139743A1 (en) 1994-03-17
JPH08502954A (ja) 1996-04-02
EP0666761A1 (en) 1995-08-16
AU5097393A (en) 1994-03-29

Similar Documents

Publication Publication Date Title
GB2265754B (en) Silicon transducer
AU1573688A (en) Membrane-gel diffusion device
AU116080S (en) Ring
HK1010797A1 (en) Hydrophone arrangement
GB9223172D0 (en) Capsule construction
GB2272345B (en) Hydrophones
EP0666761A4 (en) STIMULATION OF AN ANTI-TUMOR RESPONSE OF T-LYMPHOCYTES USING ANTI-IDIOTYPIC ANTIBODIES.
EP0586828A3 (de) Hydrophon.
IL103349A0 (en) Ring
AU4377793A (en) Alternative receptor therapy
EP0313641A4 (en) Activation antigen
GB9023730D0 (en) Explosive lines
GB9205850D0 (en) Explosive arrangements
IL102866A0 (en) Metallocenes as anti-tumor drugs
EP0554085A3 (en) Hydrophone
ZA929091B (en) Ear ring for stimulating acupuncture points.
AU4529793A (en) Endogenous ligands for cdr4 of t-cell receptor beta -chains and genes encoding the same
GB9501804D0 (en) Well-logging device
AU8123687A (en) Antiidiotypic t-cell hybridoma
HUT73886A (en) Reference elektrode free from the diffusion potential
ZA937642B (en) Explosives
BG96050A (en) Explosive
ZA938868B (en) Explosive
GB9705811D0 (en) T-cell stimulating antigens
ZA963756B (en) Explosive

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19960531

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980303